Defining the Potency of Amikacin Against Escherichia Coli, Klebsiella Pneumoniae, Pseudomonas Aeruginosa, and Acinetobacter Baumannii Derived From Chinese Hospitals Using CLSI and Inhalation-Based Breakpoints

Infection and Drug Resistance - New Zealand

doi 10.2147/idr.s161636